Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma.
Sixteen patients with advanced AIDS-related Kaposi's sarcoma received liposomal doxorubicin (Doxil, Liposome Technology, Menlo Park, California) at 20 mg/m2 every 2 or 3 weeks in an open label study, and were evaluated for efficacy and toxicity. Eleven patients achieved a partial remission and five had stable disease. The median time to achieve a maximum response was two cycles (range 1-3) and the median duration of response was 14 weeks (range 6-30). Myelosuppression was the commonest adverse event; one patient was withdrawn because of neutropenia. Other adverse events were uncommon and mild. Liposomal doxorubicin is an effective and safe single agent treatment for advanced AIDs-related Kaposi's sarcoma.
Simpson
J K
JK
Meyerstein Institute of Clinical Oncology, Middlesex Hospital, London, UK.
Miller
R F
RF
Spittle
M F
MF
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004337:Drug Carriers; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin